Stock Analiz

YD Bio Ltd YDES

Medical Specialities · data as of November 13, 2026

$4.88Market cap $346M
Open the interactive analysis →

YD Bio Ltd (YDES) is a healthcare company listed in the US with a market value of about $346M. In the twelve months to June 30, 2026 it had revenue of $1M and net income of $305762, a net margin of 24.7%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -25%.

About YD Bio

YD Bio is listed in the US and classified in medical specialities. It was profitable in 1 of the last 3 years in our data. It spends 268% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth2/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S278.9
P/B77.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-2.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)16.9%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-555.1%
ROIC (5-yr avg.)-25.2%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 3 years

Fiscal yearTTM202520242023
Revenue$1M$596817$510360$350131
Net income$305762-$8M-$1M$13560
Free cash flow-$9M-$8M-$1M-$55947
EPS (diluted)$0.00$-0.12$-0.02$0.00
Net margin24.7%-1392.6%-276.6%3.9%
ROIC——-17.5%-32.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does YD Bio pay a dividend?

Not currently.

Is YD Bio a good stock to buy?

We do not give buy or sell advice. YD Bio scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.